Difference between revisions of "Waldenström macroglobulinemia - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/fulltext " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.thelancet.com/journals/lanhae/article/PII" to "https://doi.org/10.1016/") |
||
| Line 18: | Line 18: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 33: | Line 33: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 45: | Line 45: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | ||
| − | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https:// | + | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://doi.org/10.1016/S2352-3026(16)30166-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971 PubMed] NCT00811733 |
=Relapsed or refractory= | =Relapsed or refractory= | ||
| Line 55: | Line 55: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 70: | Line 70: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1016/S2352-3026(16)30166-1 Furman et al. 2016 (GSK 110921)] |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 82: | Line 82: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | <!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] --> | ||
| − | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https:// | + | # '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://doi.org/10.1016/S2352-3026(16)30166-1 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971 PubMed] NCT00811733 |
==Panobinostat monotherapy {{#subobject:f079ae|Regimen=1}}== | ==Panobinostat monotherapy {{#subobject:f079ae|Regimen=1}}== | ||
Revision as of 19:59, 16 September 2022
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main WM regimen page to find other regimens.
3 regimens on this page
5 variants on this page
|
First-line therapy
Ofatumumab monotherapy
Regimen variant #1
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains dosing details in abstract link to PMC article PubMed NCT00811733
Relapsed or refractory
Ofatumumab monotherapy
Regimen variant #1
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains dosing details in abstract link to PMC article PubMed NCT00811733
Panobinostat monotherapy
Regimen
| Study | Evidence |
|---|---|
| Ghobrial et al. 2013 (DFCI 09-071) | Phase 2 |
Targeted therapy
- Panobinostat (Farydak) 30 mg PO 3 days per week (Mondays, Wednesdays, and Fridays)
28-day cycles
References
- DFCI 09-071: Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00936611